- Home
- TBRG vs ABOS Comparison
TBRG vs ABOS Comparison
Compare TBRG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBRG
- ABOS
- Stock Information
- Founded
- TBRG 1979
- ABOS 1996
- Country
- TBRG United States
- ABOS United States
- Employees
- TBRG N/A
- ABOS N/A
- Industry
- TBRG
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- TBRG
- ABOS Health Care
- Exchange
- TBRG NYSE
- ABOS Nasdaq
- Market Cap
- TBRG 271.5M
- ABOS 99.1M
- IPO Year
- TBRG N/A
- ABOS 2021
- Fundamental
- Price
- TBRG $21.27
- ABOS $1.56
- Analyst Decision
- TBRG Buy
- ABOS Strong Buy
- Analyst Count
- TBRG 3
- ABOS 3
- Target Price
- TBRG $14.67
- ABOS $9.33
- AVG Volume (30 Days)
- TBRG 78.7K
- ABOS 379.4K
- Earning Date
- TBRG 02-27-2025
- ABOS 11-12-2024
- Dividend Yield
- TBRG N/A
- ABOS N/A
- EPS Growth
- TBRG N/A
- ABOS N/A
- EPS
- TBRG N/A
- ABOS N/A
- Revenue
- TBRG $337,674,000.00
- ABOS N/A
- Revenue This Year
- TBRG $1.02
- ABOS N/A
- Revenue Next Year
- TBRG $6.06
- ABOS N/A
- P/E Ratio
- TBRG N/A
- ABOS N/A
- Revenue Growth
- TBRG 0.26
- ABOS N/A
- 52 Week Low
- TBRG $7.55
- ABOS $1.54
- 52 Week High
- TBRG $21.80
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- TBRG 74.93
- ABOS 30.29
- Support Level
- TBRG $20.62
- ABOS $1.69
- Resistance Level
- TBRG $21.80
- ABOS $1.88
- Average True Range (ATR)
- TBRG 0.72
- ABOS 0.13
- MACD
- TBRG 0.08
- ABOS -0.00
- Stochastic Oscillator
- TBRG 85.87
- ABOS 4.88
About TBRG TRUBRIDGE INC
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are RCM, EHR, and Patient Engagement. The company derives maximum revenue from the RCM segment.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.